Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-230X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study ; volume:22 ; number:1 ; day:16 ; month:11 ; year:2022 ; pages:1-9 ; date:12.2022
BMC gastroenterology ; 22, Heft 1 (16.11.2022), 1-9, 12.2022
- Creator
-
Johnsen, Kay-Martin
Florholmen, Jon
Moe, Øystein K.
Gundersen, Mona
Beilfuss, Julia
Kileng, Hege
Sørbye, Sveinung W.
Goll, Rasmus
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12876-022-02522-4
- URN
-
urn:nbn:de:101:1-2023012909041500824543
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Johnsen, Kay-Martin
- Florholmen, Jon
- Moe, Øystein K.
- Gundersen, Mona
- Beilfuss, Julia
- Kileng, Hege
- Sørbye, Sveinung W.
- Goll, Rasmus
- SpringerLink (Online service)
Other Objects (12)
Factors influencing the discontinuation of biologic therapies in patients with ulcerative colitis
Monitoring of anti-TNF biological treatments
Clinical outcomes of patients with remitting ulcerative colitis after discontinuation of indigo naturalis
Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis
Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB)
Stopping Anti-TNF in CD Remitters: Cons
Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)
Anti-TNF, a magic bullet in cancer immunotherapy?
Ulcerative colitis - Crohn's disease
Ulcerative Colitis: Shifting Sands
Relapse rates after elective discontinuation of anti-TNF therapy in rheumatoid arthritis: a meta-analysis and review of literature
Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment
Factors influencing the discontinuation of biologic therapies in patients with ulcerative colitis
Monitoring of anti-TNF biological treatments
Clinical outcomes of patients with remitting ulcerative colitis after discontinuation of indigo naturalis
Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis
Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB)
Stopping Anti-TNF in CD Remitters: Cons
Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)
Anti-TNF, a magic bullet in cancer immunotherapy?
Ulcerative colitis - Crohn's disease
Ulcerative Colitis: Shifting Sands
Relapse rates after elective discontinuation of anti-TNF therapy in rheumatoid arthritis: a meta-analysis and review of literature
Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment
Factors influencing the discontinuation of biologic therapies in patients with ulcerative colitis
Monitoring of anti-TNF biological treatments
Clinical outcomes of patients with remitting ulcerative colitis after discontinuation of indigo naturalis
Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis
Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB)
Stopping Anti-TNF in CD Remitters: Cons
Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)
Anti-TNF, a magic bullet in cancer immunotherapy?
Ulcerative colitis - Crohn's disease
Ulcerative Colitis: Shifting Sands
Relapse rates after elective discontinuation of anti-TNF therapy in rheumatoid arthritis: a meta-analysis and review of literature